Leukemia

Researchers are evaluating Iodine (131I) apamistamab plus HCT vs conventional care in older patients with active relapsed/refractory acute myeloid leukemia.

A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia.

A retrospective study supported the role of primary radiotherapy in early-stage follicular lymphoma.

Researchers tested the PI3K inhibitor umbralisib in patients with relapsed/refractory marginal zone lymphoma in a phase II study that was presented at the AACR Annual Meeting.

Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting.

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

The PRECIS study looked at consolidation treatment with autologous stem cell transplantation vs whole-brain radiation therapy in younger patients with CNS lymphoma.

Although many immunotherapies for AML have been explored, none have ever been shown to reduced relapse rates.

The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma patients.

The combination of ibrutinib and nivolumab showed promising clinical response in patients with Richter’s Transformation.

Is Aurora A kinase inhibitor alisertib superior to standard treatment protocol for peripheral T-cell lymphoma?

Cancer Network speaks with Peter Ruvolo, PhD, about his work investigating the role of microenvironments in cancer and treatment resistance.

Investigators evaluated whether AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients.

The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions.

Researchers evaluated the primary mechanisms governing drug resistance and relapse in patients treated with crenolanib, an FLT3 inhibitor.

A retrospective study finds that younger mantle cell lymphoma patients may achieve longer PFS with AHCT consolidation.

Allogeneic transplantation was found not to improve overall outcome, in particular for patients who achieved MRD-negative status after induction.

Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.

A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML.

Researchers reported on the impact of adding the Hedgehog pathway inhibitor glasdegib to low-dose cytarabine.

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.

The US Food and Drug Administration recently approved a new agent for treatment of adult patients with relapsed or refractory acute myeloid leukemia.

Clinicians now have a new treatment to offer elderly patients with newly diagnosed acute myeloid leukemia who have comorbidities that preclude the use of intensive chemotherapy.